Imunon Historical Balance Sheet
| IMNN Stock | USD 0.91 0.01 1.11% |
Trend analysis of Imunon Inc balance sheet accounts such as Other Current Liabilities of 4.1 M or Total Current Liabilities of 5.4 M provides information on Imunon's total assets, liabilities, and equity, which is the actual value of Imunon Inc to its prevalent stockholders. By breaking down trends over time using Imunon balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Imunon Inc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Imunon Inc is a good buy for the upcoming year.
Imunon Inventory |
|
Imunon |
About Imunon Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Imunon Inc at a specified time, usually calculated after every quarter, six months, or one year. Imunon Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Imunon and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Imunon currently owns. An asset can also be divided into two categories, current and non-current.
Imunon Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Imunon assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Imunon Inc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Imunon balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Imunon Inc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most accounts from Imunon's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Imunon Inc current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Imunon's Liabilities And Stockholders Equity is very stable compared to the past year. As of the 19th of January 2025, Other Current Assets is likely to grow to about 3.1 M, while Short and Long Term Debt Total is likely to drop about 1.8 M.
| 2022 | 2023 | 2024 | 2025 (projected) | Short and Long Term Debt Total | 6.3M | 1.6M | 1.9M | 1.8M | Total Assets | 44.0M | 21.9M | 25.2M | 28.8M |
Imunon balance sheet Correlations
Click cells to compare fundamentals
Imunon Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Imunon balance sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 37.5M | 74.0M | 44.0M | 21.9M | 25.2M | 28.8M | |
| Short Long Term Debt Total | 6.2M | 6.6M | 6.3M | 1.6M | 1.9M | 1.8M | |
| Other Current Liab | 2.5M | 3.2M | 4.8M | 3.4M | 3.9M | 4.1M | |
| Total Current Liabilities | 6.8M | 6.8M | 10.0M | 7.4M | 8.5M | 5.4M | |
| Total Stockholder Equity | 18.6M | 55.8M | 29.3M | 13.4M | 15.4M | 15.9M | |
| Property Plant And Equipment Net | 1.3M | 1.4M | 754K | 2.3M | 2.7M | 2.8M | |
| Net Debt | (11.0M) | (13.0M) | (5.2M) | (4.2M) | (3.8M) | (4.0M) | |
| Retained Earnings | (312.0M) | (332.8M) | (368.7M) | (388.2M) | (349.4M) | (331.9M) | |
| Accounts Payable | 2.2M | 2.5M | 3.6M | 3.5M | 4.0M | 2.4M | |
| Cash | 17.2M | 19.6M | 11.5M | 5.8M | 6.7M | 7.9M | |
| Non Current Assets Total | 18.7M | 22.1M | 6.8M | 3.7M | 4.2M | 4.0M | |
| Non Currrent Assets Other | 58.8K | 6M | 4.5M | 50K | 45K | 42.8K | |
| Cash And Short Term Investments | 17.2M | 49.5M | 32.9M | 15.7M | 18.1M | 16.5M | |
| Net Receivables | 68.3K | 21.4K | 108.8K | 128.9K | 116.0K | 110.2K | |
| Common Stock Shares Outstanding | 2.1M | 5.8M | 7.1M | 9.0M | 10.4M | 10.9M | |
| Liabilities And Stockholders Equity | 37.5M | 74.0M | 44.0M | 21.9M | 25.2M | 28.8M | |
| Non Current Liabilities Total | 12.2M | 11.5M | 4.6M | 1.1M | 1.3M | 1.2M | |
| Other Current Assets | 3.3M | 2.4M | 4.0M | 2.5M | 2.9M | 3.1M | |
| Other Stockholder Equity | 330.2M | 388.5M | 397.9M | 401.4M | 461.6M | 484.7M | |
| Total Liab | 18.9M | 18.3M | 14.6M | 8.5M | 9.8M | 12.8M | |
| Total Current Assets | 18.8M | 51.9M | 37.2M | 18.2M | 21.0M | 19.2M | |
| Accumulated Other Comprehensive Income | 0.0 | (8K) | 27K | 60.8K | 69.9K | 73.4K | |
| Short Term Debt | 1.6M | 548.9K | 1.7M | 485.4K | 558.2K | 530.3K | |
| Intangible Assets | 16.3M | 16.1M | 13.5M | 13.4M | 15.4M | 16.1M | |
| Common Stock | 407.0K | 58K | 74K | 94.0K | 84.6K | 80.4K | |
| Short Term Investments | 0.0 | 29.9M | 21.4M | 9.9M | 11.3M | 12.7M | |
| Net Tangible Assets | (3.5M) | 3.2M | 42.4M | 29.3M | 33.7M | 35.4M | |
| Other Assets | 1.9M | 7.6M | 6.1M | 1.0 | 1.15 | 1.09 | |
| Long Term Debt | 8.0M | 3.9M | 5.9M | 4.6M | 4.1M | 5.1M | |
| Net Invested Capital | 23.7M | 61.7M | 35.4M | 13.4M | 12.0M | 11.4M | |
| Capital Stock | 407.0K | 57.7K | 74K | 94.0K | 84.6K | 140.5K | |
| Net Working Capital | 12.1M | 45.2M | 27.1M | 10.8M | 12.5M | 23.0M | |
| Property Plant Equipment | 1.8M | 1.3M | 1.2M | 704.2K | 809.8K | 1.2M | |
| Capital Lease Obligations | 1.1M | 779.6K | 231K | 1.6M | 1.5M | 849.7K | |
| Property Plant And Equipment Gross | 4.6M | 1.4M | 754K | 4.4M | 4.0M | 2.6M |
Pair Trading with Imunon
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Imunon position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Imunon will appreciate offsetting losses from the drop in the long position's value.Moving against Imunon Stock
The ability to find closely correlated positions to Imunon could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Imunon when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Imunon - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Imunon Inc to buy it.
The correlation of Imunon is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Imunon moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Imunon Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Imunon can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Imunon Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Imunon. If investors know Imunon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Imunon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Imunon Inc is measured differently than its book value, which is the value of Imunon that is recorded on the company's balance sheet. Investors also form their own opinion of Imunon's value that differs from its market value or its book value, called intrinsic value, which is Imunon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Imunon's market value can be influenced by many factors that don't directly affect Imunon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Imunon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Imunon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Imunon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.